Furthermore, suppression of CRMP2 phosphorylation has been found to improve learning and memory deficits in an AD model [51] and ameliorate axonopathy in a multiple sclerosis model [13], thus pointing to CRMP2 as a therapeutic target in axonopathy-related neurodegenerative diseases. Here, DPYSL2 is linked to multiple sclerosis.